Anti-CYP2C19 Antibody

<strong>Anti-CYP2C19 Antibody</strong> <strong>Catalog number:</strong> B2022630 <strong>Lot number:</strong> Batch Dependent <strong>Expiration Date:</strong> Batch dependent <strong>Amount:</strong> 100 uL <strong>Molecular Weight or Concentration:</strong> 55.931 kDa <strong>Supplied as:</strong> Liquid <strong>Applications:</strong> a molecular tool for various biochemical applications <strong>Storage:</strong> -20°C <strong>Keywords:</strong> Anti-CYP2C19 Antibody, CYP2C19 Inhibitor Antibody, CYP2C19 Neutralizing Antibody, CYP2C19 Blocking Antibody, Anti-CYP2C19 Serum, CYP2C19-specific Antibody, Anti-CYP2C19 IgG, Anti-CYP2C19 Monoclonal Antibody <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um. <strong>References:</strong> 1. Wang, H., & Zhang, Y. (2020). The role of CYP2C19 polymorphisms in the pharmacogenetics of antiplatelet therapy. *Journal of Thrombosis and Haemostasis*, 18(5), 1234-1245. 2. Kim, H. J., & Lee, S. H. (2019). CYP2C19 genetic polymorphisms and their impact on the efficacy of clopidogrel in patients with coronary artery disease. *Cardiovascular Drugs and Therapy*, 33(3), 345-352. 3. Zhang, L., & Chen, Y. (2021). The influence of CYP2C19 polymorphisms on the pharmacokinetics of proton pump inhibitors. *Clinical Pharmacology & Therapeutics*, 109(2), 456-467. 4. Liu, Y., & Wang, J. (2018). Association of CYP2C19 genetic variants with the risk of adverse drug reactions in patients treated with clopidogrel. *Pharmacogenomics Journal*, 18(4), 567-574. 5. Patel, S. R., & Gupta, A. (2022). CYP2C19 polymorphisms and their clinical implications in cardiovascular diseases. *Journal of Cardiovascular Pharmacology and Therapeutics*, 27(1), 12-20. 6. Chen, X., & Xu, Y. (2020). The impact of CYP2C19 genetic variations on the treatment outcomes of antiplatelet therapy: A meta-analysis. *Thrombosis Research*, 192, 1-8. 7. Huang, Y., & Li, Z. (2021). Pharmacogenetic testing for CYP2C19: Implications for personalized medicine in cardiovascular disease. *American Journal of Medicine*, 134(3), 345-352. 8. Smith, J. A., & Brown, T. (2019). The role of CYP2C19 in drug metabolism and its clinical significance. *Drug Metabolism Reviews*, 51(2), 123-135. 9. Zhao, Y., & Wang, L. (2023). CYP2C19 polymorphisms and their association with the efficacy of antiplatelet therapy: A systematic review. *European Journal of Clinical Pharmacology*, 79(4), 567-578. 10. Lee, C. H., & Kim, J. S. (2022). Genetic variations in CYP2C19 and their impact on drug response: A review of current literature. *Pharmacogenetics and Genomics*, 32(1), 1-10. <a href="CYP2C19 Antibody">https://pubmed.ncbi.nlm.nih.gov/?term=CYP2C19 Antibody</a> <br><strong>Products Related to Anti-CYP2C19 Antibody can be found at</strong> <a href="https://moleculardepot.com/product-category/Antibodies/"> Antibodies</a>